about
A unified approach to the important protein kinase inhibitor balanol and a proposed analogueProtein kinase C delta is phosphorylated on five novel Ser/Thr sites following inducible overexpression in human colorectal cancer cellsARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.Conformationally constrained analogues of diacylglycerol. 29. Cells sort diacylglycerol-lactone chemical zip codes to produce diverse and selective biological activitiesProtein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10.Phosphorylation of Cdc42 effector protein-4 (CEP4) by protein kinase C promotes motility of human breast cellsPKC activation by resveratrol derivatives with unsaturated aliphatic chainThe bryostatin 1 A-ring acetate is not the critical determinant for antagonism of phorbol ester-induced biological responses.Clinicopathological correlation and prognostic significance of protein kinase cα overexpression in human gastric carcinoma.The osteogenic or adipogenic lineage commitment of human mesenchymal stem cells is determined by protein kinase C deltaTargeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.Characterization of an environmental DNA-derived gene cluster that encodes the bisindolylmaleimide methylarcyriarubinCombined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.Wealth of opportunity - the C1 domain as a target for drug development.A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis.Analysis of substrates of protein kinase C isoforms in human breast cells by the traceable kinase method.Protein kinase Calpha-induced derepression of the human luteinizing hormone receptor gene transcription through ERK-mediated release of HDAC1/Sin3A repressor complex from Sp1 sites.Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.Characterization of the differential roles of the twin C1a and C1b domains of protein kinase C-deltaRecurrent head and neck cancer: current treatment and future prospects.Protein kinase C, an elusive therapeutic target?Absolute quantitation of endogenous proteins with precision and accuracy using a capillary Western system.Conformationally constrained analogues of diacylglycerol (DAG). 31. Modulation of the biological properties of diacylgycerol lactones (DAG-lactones) containing rigid-rod acyl groups separated from the core lactone by spacer units of different lengthSelf-assembly and lipid interactions of diacylglycerol lactone derivatives studied at the air/water interface.Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ.Protein kinase C inhibitors: a patent review (2010 - present).Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy.Protein kinase C: an attractive target for cancer therapy.Gabapentin inhibits central sensitization during migraine.
P2860
Q24616153-DB558900-2CFC-4FCF-9F06-F9FC3D49BCFDQ28255129-D937A725-C9AF-4171-BEC0-5FA32389F2D0Q30486336-3AE8F132-F49B-459C-8ABE-B88BCB5ED085Q33359658-9B65B2B4-787C-4F03-BAF5-27A990A561B4Q33569854-82B9F28B-AD9F-4687-9A33-2914DA0FFDEBQ33888968-0770F790-6ED9-41FC-9C1F-A319834791FEQ34170805-57D211F6-493B-4D52-B2E6-D96BE7A5893DQ34534789-4322B28D-CEB5-406B-8E20-F5D08A45D8A5Q34607325-2CA27E59-FB44-4261-9586-8F36294B6C2DQ34611517-ED9870F9-02A8-4362-97FD-2217D94D8DF3Q34643586-74C1D5D4-B3D2-46C0-9AB5-65AEDC765D42Q34987170-97C0F0BE-D160-46C2-8CA1-240D1786678EQ35125453-40343BC5-F9CA-45AD-86B2-57194A0A34A0Q35915107-0D85CC5E-E1E3-4C48-813D-0A97E6F94DE7Q36168226-6450833A-AD2E-4D03-83D7-2F311612FCAFQ36244135-9CFE678B-DA1F-47A9-A972-F325F04CA20BQ36252647-B1072E20-7BB8-4761-B783-F0F43AB35E4EQ36710187-BB142DE8-3560-4EBF-B0A5-B66CB273840CQ36781257-DBD02BD4-F143-4698-A711-BE4206D1EF58Q37036491-822991D1-D7EE-4A64-93E8-C80552EE1B7CQ37118936-E2AE75F1-ECD6-4C94-8455-5B5F02B40A49Q37141320-BDF93E60-D38F-4F61-B46F-8F064ED96DB7Q37247078-4944547C-1E3B-4B8C-B7BC-CB30254DE661Q37255503-4AE1B5A6-3F6D-4228-8068-58DE3DC9D843Q37372984-3101F9ED-6724-46F3-AF31-B0BB67D09757Q38005950-7D777DF3-F409-4E08-97EA-C386E0F83047Q38116565-C1C69133-331C-442F-B2F2-C18B0F727B0EQ38200047-10C57EEC-7D14-494C-A10D-E1E8CFEBB960Q38748961-5919F01E-8020-4DA6-8BE7-76C731FB4859Q38960661-6427FEE9-43A4-4761-A0B6-143D749A7D97Q39275789-47FA8839-E7CB-48A3-A893-686206DCB5A5Q39349244-596AB0FB-40BA-4BE8-B730-BAD339CF1E3FQ41971372-24F0A3C8-2D60-47C4-8FF4-1E4C2C128F84Q42845105-C133699E-6387-4EF8-8311-416BF30D49D5
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Protein kinase C as a therapeutic target.
@ast
Protein kinase C as a therapeutic target.
@en
type
label
Protein kinase C as a therapeutic target.
@ast
Protein kinase C as a therapeutic target.
@en
prefLabel
Protein kinase C as a therapeutic target.
@ast
Protein kinase C as a therapeutic target.
@en
P1476
Protein kinase C as a therapeutic target.
@en
P2093
Beverly A Teicher
P304
P356
10.1158/1078-0432.CCR-06-0945
P407
P577
2006-09-01T00:00:00Z